Information  X 
Enter a valid email address

Immupharma PLC (IMM)

  Print      Mail a friend       Annual reports

Monday 17 December, 2018

Immupharma PLC

Appointment of Nominated Adviser

RNS Number : 5484K
Immupharma PLC
17 December 2018


                                                                                                                                                                 17 December 2018



ImmuPharma PLC

("ImmuPharma" or the "Company")




ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company is pleased to announce the appointment of SPARK Advisory Partners Limited ("SPARK") as the Company's Nominated Advisor ("NOMAD"), with immediate effect.


Commenting on the appointment, ImmuPharma's Chairman, Tim McCarthy, said:


"I am delighted to announce the appointment of SPARK as the Company's NOMAD. We look forward to working with the team going forward, alongside our joint brokers, Stanford Capital Partners and SI Capital."



This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. ("MAR")



For further information please contact:


ImmuPharma plc (

+ 44 (0) 207 152 4080

Tim McCarthy, Chairman


Lisa Baderoon, Head of Investor Relations

+ 44 (0) 7721 413496


SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

Vassil Kirtchev


Stanford Capital Partners (Joint Broker)

Patrick Claridge, John Howes


SI Capital (Joint Broker)

Nick Emerson


+44 (0) 203 368 8974




+44 (0) 203 815 8880



+44 (0) 1483 413500




About SPARK Advisory Partners Limited


SPARK Advisory Partners was established in January 2012 by its founding partners to provide product independent corporate finance advice to mid-market companies, owner managers and shareholders.
SPARK is owned by its partners who have worked together for many years. The team has a broad cross section of skills and transaction experience, encompassing M&A, private equity, public capital raisings and debt advisory services. For more information go to:



















This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t